Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Rizwan I. Hussain"'
Autor:
Aldo P. Maggioni, Andrew L. Clark, Vivencio Barrios, Thibaud Damy, Jaroslaw Drozdz, Candida Fonseca, Lars H. Lund, Stefanie Kalus, Philippe C. Ferber, Rizwan I. Hussain, Cornelia Koch, Uwe Zeymer, the ARIADNE investigators
Publikováno v:
ESC Heart Failure, Vol 9, Iss 6, Pp 4209-4218 (2022)
Abstract Aims ARIADNE aimed to assess the association between effects of sacubitril/valsartan and no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical outcomes (cause‐specific mortality and hospitalizati
Externí odkaz:
https://doaj.org/article/1e95d61631394164bb9aeae759fd023a
Autor:
Einar Sjaastad Nordén, Bård Andre Bendiksen, Henriette Andresen, Kaja Knudsen Bergo, Emil Knut Espe, Almira Hasic, Ida Marie Hauge‐Iversen, Ioanni Veras, Rizwan I. Hussain, Ivar Sjaastad, Geir Christensen, Alessandro Cataliotti
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 918-927 (2021)
Abstract Aims Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with va
Externí odkaz:
https://doaj.org/article/ef9c007a98994656b7f13eb160a5937f
Autor:
Almira Hasic, Einar Sjaastad Norden, Henriette Andresen, Geir Christensen, Ivar Sjaastad, Bård Andre Bendiksen, Ioanni Veras, Rizwan I Hussain, Emil K. S. Espe, Ida Marie Hauge-Iversen, Alessandro Cataliotti, Kaja Knudsen Bergo
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 918-927 (2021)
ESC Heart Failure
ESC Heart Failure
Aims Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with valsartan i
Autor:
Jessica Schorr, Frank Edelmann, Josep Comin-Colet, Rizwan I Hussain, Massimo F Piepoli, Tiny Jaarsma, Laurent Ecochard
Publikováno v:
European Journal of Heart Failure. 22:1724-1733
Aim In PARADIGM-HF, sacubitril/valsartan demonstrated superiority to enalapril in reducing mortality and morbidity in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Several patient-centred outcomes like improved physical act
Autor:
Rizwan I Hussain, FD Richard Hobbs, Yigal M. Pinto, Philippe Ferber, Benoit Lequeux, Héctor Bueno, Matthias Pauschinger, Finn Gustafsson, Cristina Vitale, Michael Obermeier
Publikováno v:
Open Heart, Vol 8, Iss 2 (2021)
Hobbs, F D R, Hussain, R I, Vitale, C, Pinto, Y M, Bueno, H, Lequeux, B, Pauschinger, M, Obermeier, M, Ferber, P C & Gustafsson, F 2021, ' PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER) : A real-world study ', Open Heart, vol. 8, no. 2, e001630, pp. 1-10 . https://doi.org/10.1136/openhrt-2021-001630
Open Heart
Open heart, 8(2):e001630. BMJ Publishing Group
Hobbs, F D R, Hussain, R I, Vitale, C, Pinto, Y M, Bueno, H, Lequeux, B, Pauschinger, M, Obermeier, M, Ferber, P C & Gustafsson, F 2021, ' PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER) : A real-world study ', Open Heart, vol. 8, no. 2, e001630, pp. 1-10 . https://doi.org/10.1136/openhrt-2021-001630
Open Heart
Open heart, 8(2):e001630. BMJ Publishing Group
ObjectiveTo assess current management practice of heart failure with reduced ejection fraction (HFrEF) in multinational primary care (PC) and determine whether N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP)-guided referral of HFrEF patients f
Autor:
Frank Edelmann, Philippe Ferber, Massimo F Piepoli, Ramon Dosantos, Josep Comin-Colet, Tiny Jaarsma, Rizwan I Hussain
Aims OUTSTEP-HF compared the effect of sacubitril/valsartan vs. enalapril on 6-min walk test (6MWT) distance, non-sedentary daytime physical activity and heart failure (HF) symptoms in patients with HF with reduced ejection fraction (HFrEF). Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b207cfa6cc960e8712f6df7d751133
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-172862
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-172862
Autor:
Ariadne investigators, Andrew L. Clark, Cornelia Koch, Aldo P. Maggioni, Thibaud Damy, Vivencio Barrios, Lars Lund, Candisda Fonseca, Stefanie Kalus, Jarosław Drożdż, Uwe Zeymer, Rizwan I Hussain, Philippe Ferber
Publikováno v:
European heart journal. Quality of careclinical outcomes. 8(4)
Aims To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient s
Autor:
Frank, Edelmann, Tiny, Jaarsma, Josep, Comin-Colet, Jessica, Schorr, Laurent, Ecochard, Rizwan I, Hussain, Massimo F, Piepoli
Publikováno v:
European journal of heart failureReferences. 22(9)
In PARADIGM-HF, sacubitril/valsartan demonstrated superiority to enalapril in reducing mortality and morbidity in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Several patient-centred outcomes like improved physical activit
Autor:
Peter, Molenaar, Torsten, Christ, Rizwan I, Hussain, Andreas, Engel, Emanuel, Berk, Katherine T, Gillette, Lu, Chen, Alejandro, Galindo-Tovar, Kurt A, Krobert, Ursula, Ravens, Finn Olav, Levy, Alberto J, Kaumann
Publikováno v:
British journal of pharmacology. 169(3)
PDE3 and/or PDE4 control ventricular effects of catecholamines in several species but their relative effects in failing human ventricle are unknown. We investigated whether the PDE3-selective inhibitor cilostamide (0.3-1 μM) or PDE4 inhibitor rolipr
Autor:
Yigal M Pinto, Matthias Pauschinger, Finn Gustafsson, FD Richard Hobbs, Hector Bueno, Michael Obermeier, Benoit Lequeux, Rizwan I Hussain, Cristina Vitale, Philippe C Ferber
Publikováno v:
Open Heart, Vol 8, Iss 2 (2021)
Externí odkaz:
https://doaj.org/article/a579d869b4364675bd5e49796723bfec